Jazz’ Rylaze granted expanded FDA approval for new dosing option
Jazz Pharmaceuticals announced that the US Food and Drug Administration (FDA) has expanded approval for Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn). In June last year, Rylaze was approved in